Patent · US Active

Use of rotigotine for the treatment of depression

US8754119B2 · kind B2 · utility

16Cited by

48References

62Claims

0Family size

Assignee

UCB Pharma GMBH · DE

Inventors

Dieter Scheller · Brussels, BE
Alexander Breidenbach · Weil am Rhein, DE
Norma Selve · Troisdorf, DE

Key dates

Filing date	Jul 22, 2004
Grant date	Jun 17, 2014
Priority date	—
Expiry date	Aug 8, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of rotigotine [(−)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol] and its prodrugs and pharmaceutically acceptable salts for producing a pharmaceutical agent for treating depression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.